KR20140099315A - Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체 - Google Patents

Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체 Download PDF

Info

Publication number
KR20140099315A
KR20140099315A KR1020147018336A KR20147018336A KR20140099315A KR 20140099315 A KR20140099315 A KR 20140099315A KR 1020147018336 A KR1020147018336 A KR 1020147018336A KR 20147018336 A KR20147018336 A KR 20147018336A KR 20140099315 A KR20140099315 A KR 20140099315A
Authority
KR
South Korea
Prior art keywords
her3
antibody
fragment
amino acid
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147018336A
Other languages
English (en)
Korean (ko)
Inventor
빈프리트 엘리스
세스 에텐버그
앤드류 폴 가르너
니콜 하우브스트
헤더 휴엣
크리스티안 카르스텐 실베스터 쿤즈
엘리자베스 안 라이징거 스프라그
칭 셍
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140099315A publication Critical patent/KR20140099315A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020147018336A 2011-12-05 2012-12-04 Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체 Withdrawn KR20140099315A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05
US61/566,912 2011-12-05
PCT/IB2012/056956 WO2013084151A2 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Publications (1)

Publication Number Publication Date
KR20140099315A true KR20140099315A (ko) 2014-08-11

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147018336A Withdrawn KR20140099315A (ko) 2011-12-05 2012-12-04 Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체

Country Status (16)

Country Link
EP (1) EP2788381A2 (enrdf_load_html_response)
JP (1) JP2015500830A (enrdf_load_html_response)
KR (1) KR20140099315A (enrdf_load_html_response)
CN (1) CN104093742A (enrdf_load_html_response)
AR (1) AR089085A1 (enrdf_load_html_response)
AU (1) AU2012349739A1 (enrdf_load_html_response)
BR (1) BR112014013495A2 (enrdf_load_html_response)
CA (1) CA2857939A1 (enrdf_load_html_response)
EA (1) EA201491120A1 (enrdf_load_html_response)
IL (1) IL232950A0 (enrdf_load_html_response)
IN (1) IN2014CN04374A (enrdf_load_html_response)
MX (1) MX2014006731A (enrdf_load_html_response)
SG (1) SG11201402784WA (enrdf_load_html_response)
TW (1) TW201331225A (enrdf_load_html_response)
UY (1) UY34488A (enrdf_load_html_response)
WO (1) WO2013084151A2 (enrdf_load_html_response)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180059180A (ko) * 2016-11-25 2018-06-04 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
ES2833599T3 (es) * 2014-02-28 2021-06-15 Merus Nv Anticuerpo que se une a ERBB-2 y ERBB-3
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
CN104530237B (zh) * 2014-12-31 2017-09-05 百泰生物药业有限公司 抗Her1的治疗性抗体
NZ742290A (en) 2015-10-23 2019-11-29 Merus Nv Binding molecules that inhibit cancer growth
JP6729926B2 (ja) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ＥｒｂＢ３活性化に伴うシグナルの伝達抑制物質及びそのスクリーニング方法
ES3037145T3 (en) * 2016-09-15 2025-09-29 Univ Stuttgart Antigen binding protein against her3
MX2019011660A (es) 2017-03-31 2019-11-18 Merus Nv Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
CA3063849A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MA49846B1 (fr) 2017-08-09 2025-05-30 Merus N.V. Anticorps liant egfr et cmet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AU2010242914B2 (en) * 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
CN105999263B (zh) * 2009-11-13 2021-06-29 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
RU2568051C2 (ru) * 2010-04-09 2015-11-10 Авео Фармасьютикалз, Инк. АНТИТЕЛА К ErbB3
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
DK2707391T3 (en) * 2011-05-13 2018-02-05 Gamamabs Pharma ANTIBODIES AGAINST HER3
WO2013016714A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180059180A (ko) * 2016-11-25 2018-06-04 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
AR089085A1 (es) 2014-07-30
EA201491120A1 (ru) 2015-07-30
IL232950A0 (en) 2014-07-31
BR112014013495A8 (pt) 2017-06-13
TW201331225A (zh) 2013-08-01
BR112014013495A2 (pt) 2017-06-13
SG11201402784WA (en) 2014-06-27
WO2013084151A2 (en) 2013-06-13
UY34488A (es) 2013-07-31
EP2788381A2 (en) 2014-10-15
JP2015500830A (ja) 2015-01-08
AU2012349739A1 (en) 2014-06-26
CA2857939A1 (en) 2013-06-13
IN2014CN04374A (enrdf_load_html_response) 2015-09-04
CN104093742A (zh) 2014-10-08
MX2014006731A (es) 2015-06-04
WO2013084151A3 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
JP6771002B2 (ja) 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
KR20140099315A (ko) Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
KR102218497B1 (ko) 표피 성장 인자 수용체 3 (her3)에 대한 항체
KR20140103135A (ko) Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
KR102492057B1 (ko) 골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
US10538587B2 (en) Antibodies against notch 3
HK1182118A (en) Antibodies for epidermal growth factor receptor 3 (her3)
HK1182118B (en) Antibodies for epidermal growth factor receptor 3 (her3)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140702

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid